Close

SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD Aug 7, 2023 06:24AM
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Aug 4, 2023 10:42PM
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone Mar 8, 2023 06:30AM
Biogen (BIIB), Sage Therapeutics (SAGE) announce FDA acceptance of NDA for zuranolone to treat MDD and PPD Feb 6, 2023 06:51AM
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Feb 6, 2023 06:30AM


Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Dec 6, 2022 06:30AM Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Nov 22, 2022 07:00AM Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Oct 17, 2022 06:33AM SAGE (SAGE) and Biogen (BIIB) Report Further Analyses from Phase 3 Study of Zuranolone
Oct 17, 2022 06:30AM Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Sep 19, 2022 06:30AM Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
Jun 1, 2022 06:30AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
Jun 1, 2022 06:30AM Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
May 2, 2022 06:31AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Initiate Rolling NDA Submission for Zuranolone
May 2, 2022 06:30AM Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD
Feb 16, 2022 07:00AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints
Feb 16, 2022 07:00AM Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of
Dec 8, 2021 06:31AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce New Analyses from LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at ACNP Congress
Dec 8, 2021 06:30AM Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
Dec 1, 2021 06:31AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Dec 1, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Oct 19, 2021 06:33AM SAGE Therapeutics (SAGE), Biogen (BIIB) to Submit NDA for Zuranolone to FDA in Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
Oct 19, 2021 06:30AM Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Oct 4, 2021 06:31AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at ECNP Congress
Oct 4, 2021 06:30AM Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychop
Jun 15, 2021 06:32AM Sage Therapeutics (SAGE), Biogen (BIIB) Phase 3 for Zuranolone for Major Depressive Disorder Shows Statistically Significant Improvement
Jun 15, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Jun 15, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Jun 15, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Apr 12, 2021 07:01AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Apr 12, 2021 07:00AM Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Nov 27, 2020 07:31AM Biogen (BIIB) and Sage Therapeutics (SAGE) Announce Pact to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 27, 2020 07:30AM Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 27, 2020 07:30AM Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 27, 2020 07:30AM Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Apr 8, 2020 09:31AM Pre-Open Stock Movers 04/08: (GNMK) (NVAX) (APT) Higher; (TAL) (EHTH) (W) Lower (more...)
Apr 7, 2020 05:41PM After-Hours Stock Movers 04/07: (GNMK) (PINS) (PYPL) Higher; (TAL) (IQ) (SQ) Lower (more...)
Jul 1, 2019 09:01AM Ligand Pharma (LGND) announces Sage Therapeutics has launched ZULRESSO
May 23, 2019 09:06AM Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
Mar 21, 2019 09:04AM Ligand Pharma (LGND) to receive $3 million milestone payment as result of FDA’s approval of Sage's ZULRESSOTM
Mar 21, 2019 09:00AM Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Jun 12, 2018 09:26AM Pre-Open Movers 06/12: (GLMD) (RH) (PLAY) Higher; (IDRA) (JCAP) (IMMU) Lower (more...)
Feb 14, 2017 03:41PM JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
Nov 14, 2016 07:49AM JANA Partners Enters Kate Spade (KATE), Select Medical (SEM), Twitter (TWTR) (more...)
Sep 8, 2016 09:29AM Pre-Open Stock Movers 09/08: (RPRX) (RAD) (JUNO) Higher; (GEVO) (NLST) (TSCO) (PIR) Lower (more...)
May 24, 2016 10:24AM Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
Mar 29, 2016 02:53PM INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Sage Therapeutics, Inc. and Advises Investors With Losses in Excess of $50,000 to Contact the Firm
Mar 23, 2016 06:45PM IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Sage Therapeutics, Inc. and Advises Investors with Losses in Excess of $50,000 to Contact the Firm
Jul 8, 2015 10:00AM SAGE Therapeutics, Inc. (Nasdaq: SAGE) to Ring The Nasdaq Stock Market Opening Bell
Jul 8, 2015 10:00AM SAGE Therapeutics, Inc. (Nasdaq: SAGE) to Ring The Nasdaq Stock Market Opening Bell